EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

L26/P-504 Atosiban administration before frozen embryo transfer is associated with higher clinical pregnancy rates: a randomized controlled trial

K.D. Nayar, S. Singh, M. Sachdeva, A. Arora, G. Kant, K. Nayar

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.837 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von K.D. Nayar und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does atosiban administration, a competitive oxytocin receptor antagonist, prior to frozen embryo transfer is associated with higher clinical pregnancy rates compared with standard FET protocols? Summary answer Pre-transfer atosiban significantly enhances clinical pregnancy rates in frozen embryo transfer cycles compared with standard FET protocols. What is known already Excessive uterine contractions at embryo transfer have been associated with reduced implantation and pregnancy rates. Pharmacological suppression of uterine activity using atosiban has shown variable benefit, with most evidence derived from fresh embryo transfer cycles. Data in frozen embryo transfer cycles are scarce and inconsistent, despite their increasing use in contemporary IVF practice. Current guidelines do not recommend routine atosiban use due to insufficient high-quality evidence, highlighting the need for well-designed randomized controlled trials in clearly defined frozen embryo transfer populations. Study design, size, duration This prospective randomized controlled trial was conducted at a tertiary IVF centre in New Delhi between February 2025 to September 2025. One hundred women undergoing frozen embryo transfer were randomly allocated in equal numbers, Group A (n = 50) to receive intravenous atosiban prior to embryo transfer or Group B (n = 50 Control ) to receive standard frozen embryo transfer without atosiban. Participants/materials, setting, methods Women aged 23–35 years with body mass index <30 kg/m², normal uterine cavity, endometrial thickness ≥7 mm, and transfer of two grade A blastocysts were included. Participants received intravenous atosiban (6.75 mg) 30 minutes before embryo transfer or standard care. Clinical pregnancy was confirmed by ultrasonography following positive serum β-hCG. Main results and the role of chance Baseline demographic and clinical characteristics, including age, infertility duration, anti-Müllerian hormone, antral follicle count, and hormonal parameters, were comparable between groups. The clinical pregnancy rate was significantly higher in the atosiban group than in controls (58% vs. 38%; absolute difference 20%; p < 0.05). Implantation rates were higher with atosiban (33.3% vs. 23.8%), although this difference did not reach statistical significance (p = 0.12). Biochemical pregnancy rates were also numerically higher in the atosiban group (20% vs. 14%; p = 0.42). First-trimester miscarriage rates were lower following atosiban administration (17.2% vs. 21.1%), without statistical significance. The magnitude and consistency of effect across outcomes suggest a clinically meaningful benefit, with secondary outcomes likely underpowered. Limitations, reasons for caution The study was limited by its single-centre design and sample size, potentially underpowering secondary outcomes. Generalisability to broader frozen embryo transfer populations requires confirmation. Wider implications of the findings Atosiban may offer a low-risk, easily implementable strategy to improve frozen embryo transfer outcomes. These findings support further evaluation in larger multicentre randomized trials. Trial registration number Yes

Zitieren

APA

Nayar, K., Singh, S., Sachdeva, M., Arora, A., Kant, G., & Nayar, K. (2026). L26/P-504 Atosiban administration before frozen embryo transfer is associated with higher clinical pregnancy rates: a randomized controlled trial. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.837

Vancouver

Nayar K, Singh S, Sachdeva M, Arora A, Kant G, Nayar K. L26/P-504 Atosiban administration before frozen embryo transfer is associated with higher clinical pregnancy rates: a randomized controlled trial. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.837

BibTeX
@article{Nayar2026,
  author = {Nayar, K.D. and Singh, S. and Sachdeva, M. and Arora, A. and Kant, G. and Nayar, K.},
  title = {L26/P-504 Atosiban administration before frozen embryo transfer is associated with higher clinical pregnancy rates: a randomized controlled trial},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.837}
}
Kostenlos starten →